Barrett A J, Horowitz M M, Ash R C, Atkinson K, Gale R P, Goldman J M, Henslee-Downey P J, Herzig R H, Speck B, Zwaan F E
Department of Medicine, Medical College of Wisconsin, Milwaukee 53226.
Blood. 1992 Jun 1;79(11):3067-70.
Philadelphia chromosome (Ph1)-positive acute lymphoblastic leukemia (ALL) has a poor prognosis when treated with conventional chemotherapy. We analyzed the outcome of 67 HLA-identical sibling bone marrow transplants (BMTs) for Ph1-positive ALL reported to the International Bone Marrow Transplant Registry (IBMTR). Twenty-one of 67 (31%) transplant recipients survived in continuous complete remission more than 2 years after transplant. Two-year actuarial probabilities (95% confidence interval) of leukemia-free survival were 38% (23% to 55%) for 33 patients transplanted in first remission, 41% (23% to 61%) for 22 patients transplanted after relapse, and 25% (9% to 53%) for 12 patients failing to achieve remission with conventional chemotherapy. These data indicate that transplants are effective treatment for Ph1-positive ALL.
费城染色体(Ph1)阳性的急性淋巴细胞白血病(ALL)患者接受传统化疗时预后较差。我们分析了国际骨髓移植登记处(IBMTR)报告的67例接受 HLA 相同同胞骨髓移植(BMT)治疗的Ph1阳性ALL患者的治疗结果。67例移植受者中有21例(31%)在移植后持续完全缓解超过2年存活。首次缓解期接受移植的33例患者无白血病生存的2年精算概率(95%置信区间)为38%(23%至55%),复发后接受移植的22例患者为41%(23%至61%),传统化疗未达缓解的12例患者为25%(9%至53%)。这些数据表明移植是治疗Ph1阳性ALL的有效方法。